171 related articles for article (PubMed ID: 22001609)
1. Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.
Stone E; Chantranupong L; Gonzalez C; O'Neal J; Rani M; VanDenBerg C; Georgiou G
J Control Release; 2012 Feb; 158(1):171-9. PubMed ID: 22001609
[TBL] [Abstract][Full Text] [Related]
2. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts.
Glazer ES; Stone EM; Zhu C; Massey KL; Hamir AN; Curley SA
Transl Oncol; 2011 Jun; 4(3):138-46. PubMed ID: 21633669
[TBL] [Abstract][Full Text] [Related]
3. A bioengineered arginine-depleting enzyme as a long-lasting therapeutic agent against cancer.
Chung SF; Kim CF; Tam SY; Choi MC; So PK; Wong KY; Leung YC; Lo WH
Appl Microbiol Biotechnol; 2020 May; 104(9):3921-3934. PubMed ID: 32144472
[TBL] [Abstract][Full Text] [Related]
4. Rational design, engineer, and characterization of a novel pegylated single isomer human arginase for arginine depriving anti-cancer treatment.
Yu KM; Pang TP; Cutler M; Tian M; Huang L; Lau JY; Chung SF; Lo TW; Leung TY
Life Sci; 2021 Jan; 264():118674. PubMed ID: 33129876
[TBL] [Abstract][Full Text] [Related]
5. Mono-PEGylation of a Thermostable Arginine-Depleting Enzyme for the Treatment of Lung Cancer.
Chung SF; Kim CF; Kwok SY; Tam SY; Chen YW; Chong HC; Leung SL; So PK; Wong KY; Leung YC; Lo WH
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545874
[TBL] [Abstract][Full Text] [Related]
6. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties.
Holtsberg FW; Ensor CM; Steiner MR; Bomalaski JS; Clark MA
J Control Release; 2002 Apr; 80(1-3):259-71. PubMed ID: 11943403
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma.
Yau T; Cheng PN; Chan P; Chan W; Chen L; Yuen J; Pang R; Fan ST; Poon RT
Invest New Drugs; 2013 Feb; 31(1):99-107. PubMed ID: 22426640
[TBL] [Abstract][Full Text] [Related]
8. Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines.
Stone EM; Glazer ES; Chantranupong L; Cherukuri P; Breece RM; Tierney DL; Curley SA; Iverson BL; Georgiou G
ACS Chem Biol; 2010 Mar; 5(3):333-42. PubMed ID: 20050660
[TBL] [Abstract][Full Text] [Related]
9. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
Cheng PN; Lam TL; Lam WM; Tsui SM; Cheng AW; Lo WH; Leung YC
Cancer Res; 2007 Jan; 67(1):309-17. PubMed ID: 17210712
[TBL] [Abstract][Full Text] [Related]
10. l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells.
Fletcher M; Ramirez ME; Sierra RA; Raber P; Thevenot P; Al-Khami AA; Sanchez-Pino D; Hernandez C; Wyczechowska DD; Ochoa AC; Rodriguez PC
Cancer Res; 2015 Jan; 75(2):275-83. PubMed ID: 25406192
[TBL] [Abstract][Full Text] [Related]
11. Stable overexpression of arginase I and ornithine transcarbamylase in HepG2 cells improves its ammonia detoxification.
Tang N; Wang Y; Wang X; Zhou L; Zhang F; Li X; Chen Y
J Cell Biochem; 2012 Feb; 113(2):518-27. PubMed ID: 21938740
[TBL] [Abstract][Full Text] [Related]
12. A novel nitric oxide-based anticancer therapeutics by macrophage-targeted poly(l-arginine)-based nanoparticles.
Kudo S; Nagasaki Y
J Control Release; 2015 Nov; 217():256-62. PubMed ID: 26386436
[TBL] [Abstract][Full Text] [Related]
13. Pegylated arginase I: a potential therapeutic approach in T-ALL.
Hernandez CP; Morrow K; Lopez-Barcons LA; Zabaleta J; Sierra R; Velasco C; Cole J; Rodriguez PC
Blood; 2010 Jun; 115(25):5214-21. PubMed ID: 20407034
[TBL] [Abstract][Full Text] [Related]
14. Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia.
Morrow K; Hernandez CP; Raber P; Del Valle L; Wilk AM; Majumdar S; Wyczechowska D; Reiss K; Rodriguez PC
Leukemia; 2013 Mar; 27(3):569-77. PubMed ID: 22926702
[TBL] [Abstract][Full Text] [Related]
15. Non-degradative intracellular trafficking of highly compacted polymeric DNA nanoparticles.
Kim AJ; Boylan NJ; Suk JS; Lai SK; Hanes J
J Control Release; 2012 Feb; 158(1):102-7. PubMed ID: 22079809
[TBL] [Abstract][Full Text] [Related]
16. Conjugation to 10 kDa Linear PEG Extends Serum Half-Life and Preserves the Receptor-Binding Ability of mmTRAIL with Minimal Stimulation of PEG-Specific Antibodies.
Nie Q; Jia D; Yang H; Feng Y; Fan Q; Shi Q; Wan L; Lu X
Mol Pharm; 2017 Feb; 14(2):502-512. PubMed ID: 28029256
[TBL] [Abstract][Full Text] [Related]
17. Insights into the Structural Requirements of 2(S)-Amino-6-Boronohexanoic Acid Derivatives as Arginase I Inhibitors: 3D-QSAR, Docking, and Interaction Fingerprint Studies.
Velázquez-Libera JL; Navarro-Retamal C; Caballero J
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274146
[TBL] [Abstract][Full Text] [Related]
18. Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC).
Tsui SM; Lam WM; Lam TL; Chong HC; So PK; Kwok SY; Arnold S; Cheng PN; Wheatley DN; Lo WH; Leung YC
Cancer Cell Int; 2009 Apr; 9():9. PubMed ID: 19374748
[TBL] [Abstract][Full Text] [Related]
19. Development of Recombinant Methioninase for Cancer Treatment.
Hoffman RM; Tan Y; Li S; Han Q; Yagi S; Takakura T; Takimoto A; Inagaki K; Kudou D
Methods Mol Biol; 2019; 1866():107-131. PubMed ID: 30725412
[TBL] [Abstract][Full Text] [Related]
20. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
